Search

Displaying results 411 - 420 of 4233 in total
  1. Drug

    Imipenem

    go.drugbank.com/drugs/DB01598
    ApprovedInvestigational

    Imipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed by Merck & Co.[L7628]

  2. Drug

    Umeclidinium

    go.drugbank.com/drugs/DB09076
    ApprovedInvestigational

    [A7718,A7714] Umeclidinium was approved by the FDA in April 2014 under the brand name Incruse Ellipta as a standalone product. … Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD).

  3. Drug

    Levothyroxine

    go.drugbank.com/drugs/DB00451
    ApprovedInvestigational

    [A179935] As a result, many cardiac functions including heart rate, cardiac output, and systemic vascular resistance are closely linked to thyroid status. … [F4633] Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient

  4. Drug

    Tyloxapol

    go.drugbank.com/drugs/DB06439
    ApprovedInvestigational

    Tyloxapol is a non-ionic detergent often used as a surfactant.

  5. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). … When administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle strength and extends survival time.

  6. Drug

    Aluminum chlorohydrate

    go.drugbank.com/drugs/DB11573
    Approved

    It is also used as a coagulant in the water purification process. … It is included up to 25% in over-the-counter hygiene products as an active antiperspirant agent.

  7. Drug

    Palonosetron

    go.drugbank.com/drugs/DB00377
    ApprovedInvestigational

    As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.

  8. Drug

    Entacapone

    go.drugbank.com/drugs/DB00494
    ApprovedInvestigational

    When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration

  9. Drug

    Fulvestrant

    go.drugbank.com/drugs/DB00947
    ApprovedInvestigational

    While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with [alpelisib] for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative

  10. Drug

    Vepdegestrant

    go.drugbank.com/drugs/DB19006
    ApprovedInvestigational

    , such as cyclin-dependent kinase (CDK) 4/6 inhibitors. … [A275507, A275509] It serves as an advanced option to address the clinical challenge of endocrine-resistant breast cancer subtypes.